Skip to main content
Premium Trial:

Request an Annual Quote

SwitchGear Providing Roche's FuGene HD Reagent

This article has been corrected to note that Fugent is the owner of the FuGene technology, not Roche as previously reported.

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – SwitchGear Genomics today announced it will distribute Fugent's FuGene HD transfection reagent.

The product will be offered by Switchgear as a standalone product, as well as part of the company's LightSwitch Transfection Optimization kit.

"As part of SwitchGear's commitment to providing a complete reporter assay solution, we offer an start-to-finish system that will allow researchers to perform reporter assays quickly and easily without having to do any cloning or reagent optimization," Patrick Collin, director of R&D for the Menlo Park, Calif., company, said.

Terms of the distribution agreement were not disclosed.

SwitchGear was founded in 2005 by Stanford researchers and provides products for the study of regulatory elements in the human genome.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.